Compare Cassava Sciences Inc (FLNA) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs BlackRock TCP Capital Corp — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while BlackRock TCP Capital Corp trades at $3.34 (market cap $276.88M). The key difference: BlackRock TCP Capital Corp is far larger — about 5.2× Cassava Sciences Inc's market cap, and BlackRock TCP Capital Corp pays a 25.45% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TCPC | |
|---|---|---|
Market Cap | $53.14M | $276.88M |
Sector | Health | Financials |
52-Week High | $4.64 | $7.84 |
52-Week Low | $1.09 | $3.14 |
Enterprise Value | -$33.43M | — |
Dividend Yield | — | 25.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
BlackRock TCP Capital Corp. (TCPC) trades at $3.32, up 5.06% on the day, against a backdrop of mixed technical and fundamental signals. The stock is technically bearish with key moving averages signaling caution, while fundamental metrics show a challenging picture with negative revenue and net income, though a low P/B ratio of 0.49 suggests potential undervaluation. Recent news includes a Zacks upgrade to 'Buy' and an upcoming Q2 2026 earnings report on August 6, 2026.
The outlook for TCPC is clouded by persistent negative profitability and a shareholder lawsuit investigation, presenting significant risk. However, a discounted book value, a stable dividend, and a recent analyst upgrade offer a potential value opportunity for income-focused investors willing to tolerate high volatility and fundamental uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
